The pharmaceutical industry has also contributed to the problem. Developing new antibiotics is expensive and, paradoxically, not very profitable. Since antibiotics are used for short durations and must be reserved to prevent resistance, companies struggle to recoup research costs. Consequently, the antibiotic pipeline has dried up. While 40 new antibiotics were approved between 1980 and 2000, only 12 have been approved since 2010. The World Health Organization (WHO) has identified a ‘priority pathogen list’ of bacteria—including carbapenem-resistant Acinetobacter and drug-resistant tuberculosis—for which no effective drugs remain in development.
Antibiotic resistance occurs when bacteria evolve mechanisms to survive exposure to drugs designed to kill them. This is a natural evolutionary process, but human activities have dramatically accelerated it. The primary driver is the overuse and misuse of antibiotics. In many countries, antibiotics are available without prescription, leading to self-medication for viral infections like the common cold—against which they are useless. Even when prescribed correctly, patients often fail to complete the full course, allowing surviving bacteria to develop resistance. The pharmaceutical industry has also contributed to the
Tackling antibiotic resistance requires a multi-pronged ‘One Health’ approach that integrates human, animal, and environmental health strategies. Key measures include: enforcing prescription-only access, investing in rapid diagnostic tests to distinguish viral from bacterial infections, banning agricultural growth promoters, and creating international surveillance systems. Economic incentives for pharmaceutical companies, such as ‘subscription’ models where governments pay for access rather than volume, are also gaining traction. Public awareness campaigns remain vital, as many patients still pressure doctors for antibiotics despite knowing the risks. Consequently, the antibiotic pipeline has dried up
The consequences are already measurable. According to a 2022 report in The Lancet , approximately 1.27 million deaths were directly attributed to antibiotic-resistant infections in 2019, with nearly 5 million associated deaths. Without intervention, the Organisation for Economic Co-operation and Development (OECD) projects that by 2050, resistance could cause 10 million deaths annually—exceeding cancer’s toll. Routine medical procedures, such as hip replacements or caesarean sections, would become high-risk due to untreatable post-operative infections. Routine medical procedures
A less visible but equally significant contributor is the widespread use of antibiotics in agriculture. Globally, more than 70% of all antibiotics are used in farm animals—not only to treat sick animals but also for growth promotion and disease prevention in crowded conditions. These antibiotics enter the environment through manure and water run-off, creating ‘reservoirs’ of resistant bacteria in soil and water systems. From there, resistance genes can transfer to human pathogens.